Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 30, 2006 - Issue 2
132
Views
26
CrossRef citations to date
0
Altmetric
SHORT COMMUNICATION

Secretory Phospholipase A2 Levels in Patients with Sickle Cell Disease and Acute Chest Syndrome

, , , , , , , , , & show all
Pages 165-170 | Received 17 Apr 2005, Accepted 19 Oct 2005, Published online: 07 Jul 2009

REFERENCES

  • Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klugg PP. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994; 330(23)1639–1644, [INFOTRIEVE], [CSA]
  • Sprinkle RH, Cole T, Smith S, Buchanan GR. Acute chest syndrome in children with sickle cell disease: a retrospective analysis of 10 hospitalized cases. Am J Pediatr Hematol Oncol 1986; 8(2)105–110, [INFOTRIEVE], [CSA]
  • Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeshner E, Manci EA. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342(25)1855–1865, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vichinsky E, Williams R, Das M, Earles AN, Lewis N, Adler A, McQuitty J. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83(11)3107–3112, [INFOTRIEVE], [CSA]
  • Golden C, Styles L, Vichinsky E. Acute chest syndrome and sickle cell disease. Curr Opin Hematol 1998; 5(2)89–92, [INFOTRIEVE], [CSA]
  • Rae D, Porter J, Beechey-Newman N, Sumar N, Bennett D, Hermon-Taylor J. Type I phospholipase A2 propeptide in acute lung injury. Lancet 1994; 344(8935)1472–1473, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vadas P. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J Lab Clin Med 1984; 104(6)873–881, [INFOTRIEVE], [CSA]
  • Green J-A, Smith GM, Buchta R, Lee R, Ho KY, Rajkovic IA, Scott KF. Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation 1991; 15(5)355–367, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vadas P, Hay JB. Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can J Physiol Pharmacol 1983; 61(6)561–566, [INFOTRIEVE], [CSA]
  • Fink M. Phospholipase A2: potential mediators of the systemic inflammatory response syndrome and multiple organ dysfunction syndrome. Crit Care Med 1993; 21(7)957–959, [INFOTRIEVE], [CSA]
  • Vadas P, Schouten BD, Stefanski E, Scott K, Pruzanski W. Association of hyperphospholipasemia A2 with multiple organ system dysfunction due to salicylate intoxication. Crit Care Med 1993; 21(7)1087–1091, [INFOTRIEVE], [CSA]
  • Vichinsky E. Transfusion Therapy. Sickle Cell Disease. Basic Principles and Clinical Practice, SH Embury, RP Hebbel, N Mohandas, MH Steinberg. Raven Press, New York 1994; 781–798
  • Pruzanski W, Bogoch E, Wloch M, Vadas P. The role of phospholipase A2 in the pathophysiology of osteoarthritis. J Rheumat 1991; 27(Suppl)117–119, [CSA]
  • Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000; 86(7)718–722, [INFOTRIEVE], [CROSSREF], [CSA]
  • Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H. Circulating leves of secretory type II phospholipase A(2) predict coronary eventa in patients with coronary artery disease. Circulation 1999; 100(12)1280–1284, [INFOTRIEVE], [CSA]
  • Styles LA, Schalkwijk CG, Aarsman AJ, Vichinsky EP, Lubin BH, Kuypers FA. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996; 87(6)2573–2578, [INFOTRIEVE], [CSA]
  • Styles LA, Aarsman AJ, Larkin S, Vichinsky EP, Kuypers FA. Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood 2000; 96(9)3276–3278, [INFOTRIEVE], [CSA]
  • Pruzanski W, Vadas P. Phospholipase A2 – A mediator between proximal and distal effectors of inflammation. Immunol Today 1991; 12(5)143–146, [INFOTRIEVE], [CSA]
  • Clark MA, Chen M-J, Crooke ST, Bomalaski JS. Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem J 1988; 250(1)125–132, [INFOTRIEVE], [CSA]
  • Pfeilschifter J, Pignat W, Vosbeck K, Marki P. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem Biophys Res Commun 1989; 159(2)385–394, [INFOTRIEVE], [CROSSREF], [CSA]
  • Levy D. The fat embolism syndrome, a review. Clin Orthop Relat Res 1990, 261: 281–286, [CSA]
  • Moylan JA, Birmbaum M, Katz A, Everson MA. Fat emboli syndrome. J Trauma 1976; 16(5)341–347, [INFOTRIEVE], [CSA]
  • Ballas SK, Files B, Luchtman-Jones L, Benjamin L, Swerdlow P, Hilliard L, Coates T, Abboud M, Wojtowicz-Praga S, Grindel JM. Safety of purified Poloxamer 188 in sickle cell disease: Phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 2004; 28(2)85–102, [INFOTRIEVE], [CROSSREF], [CSA]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.